Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin - 01/09/11
Abstract |
Background: Botulinum toxin (Btx A) has recently been used in the treatment of focal hyperhidrosis. Hyperhidrosis is also an aggravating factor in nearly 40% of patients with dyshidrotic hand eczema. Objective: The objective of this study was to evaluate the effect of intradermal injections of Btx A on dermatitis in patients with vesicular hand dermatitis. Methods: Ten patients with vesicular dermatitis were treated on one hand with intradermal Btx A (mean, 162 U BOTOX, Allergan Pharmaceuticals, Irvine, Calif) with the untreated side as a control. Results: Self-assessment at follow-up 5 to 6 weeks after injection on a 5-point scale (none, slight, moderate, good, or very good effect) showed that 7 of 10 patients experienced good or very good effect. A decrease in itching was shown with a visual linear analogue scale (VAS) for itching, with mean 39% on the treated side compared with an increase by 52% on the untreated side. These findings were supported by the evaluation of clinical signs. Six of 7 patients who experienced good or very good effect also had aggravating hand sweating or worsening during the summer. Conclusion: Btx A can be a valuable alternative for patients with treatment-refractory hand eczema of the vesicular type, especially with hyperhidrosis or worsening during the summer. (J Am Acad Dermatol 2002;47:667-71.)
Le texte complet de cet article est disponible en PDF.Plan
Funding sources: The Swedish County Councils of Dalarna and Uppsala financed general costs in the study. Pharmaceutical gifts were received from Allergan Pharmaceuticals, Vasby, Sweden. |
|
Conflict of interest: None identified. |
|
Reprint requests: Carl Swartling, MD, Department of Dermatology, University Hospital, SE-751 85 Uppsala, Sweden. E-mail: carl-fredrik.swartling@hud.uas.lul.se. |
Vol 47 - N° 5
P. 667-671 - novembre 2002 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?